Cited by 610Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

Open access
Haigis, Kevin M, Kendall, Krystle R, Wang, Yufang, Cheung, Ann, Haigis, Marcia C, Glickman, Jonathan N, Niwa-Kawakita, Michiko, Sweet-Cordero, Alejandro +5 more·2008·Nature Genetics

Abstract

Kras is commonly mutated in colon cancers, but mutations in Nras are rare. We have used genetically engineered mice to determine whether and how these related oncogenes regulate homeostasis and tumorigenesis in the colon. Expression of K-Ras(G12D) in the colonic epithelium stimulated hyperproliferation in a Mek-dependent manner. N-Ras(G12D) did not alter the growth properties of the epithelium, but was able to confer resistance to apoptosis. In the context of an Apc-mutant colonic tumor, activation of K-Ras led to defects in terminal differentiation and expansion of putative stem cells within the tumor epithelium. This K-Ras tumor phenotype was associated with attenuated signaling through the MAPK pathway, and human colon cancer cells expressing mutant K-Ras were hypersensitive to inhibition of Raf, but not Mek. These studies demonstrate clear phenotypic differences between mutant Kras and Nras, and suggest that the oncogenic phenotype of mutant K-Ras might be mediated by noncanonical signaling through Ras effector pathways.

Integrity signals

Registry

Crossref · 10.1038/ng.115

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Additional biochemical, structural, and signaling distinctions have been identified between different mutant KRAS alleles, including between those at the same amino acid position.

    “Additional biochemical, structural, and signaling distinctions have been identified between different mutant alleles, including between those at the same amino acid position4,8,13–20.”
  • Mutant KRAS is more effective at promoting colonic epithelial cell proliferation in mice.

    “It has been shown that mutant KRAS is more effective at promoting colonic epithelial cell proliferation in mice (14)”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [14]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., Settleman, J., Giovannini, M., & Jacks, T.
Affiliations
  • Massachusetts General Hospital (US)
  • Massachusetts Institute of Technology (US)
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • Stanford Medicine (US)
  • University of California, San Francisco (US)
  • Inserm (FR)
  • Howard Hughes Medical Institute (US)
Corresponding author
Jacks, Tyler
Venue
Nature Genetics
Published
2008-03-30
Volume
40
Issue
5
Pages
600-608
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2044210875
Cited by
610
References
36
Citations by year
2026: 16 · 2025: 29 · 2024: 18 · 2023: 21 · 2022: 31 · 2021: 45 · 2020: 30 · 2019: 31 · 2018: 30 · 2017: 32 · 2016: 34 · 2015: 39 · 2014: 40 · 2013: 44 · 2012: 40
FWCI
17.85
Type
journal article
Language
en
Open access
Locations
  • Nature Genetics (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Howard Hughes Medical Institute
  • American Cancer Society
  • Massachusetts Institute of Technology
  • Association pour la Recherche sur le Cancer
  • National Institutes of Health (5k01ca118425-05)
  • National Cancer Institute (R01-CA 72614, P50CA127003, U01-CA84306, U54CA112967, U01 CA 84221, R01CA072614, K01-CA118425, U01CA084221, U01CA084306, R37CA072614, P30CA014051, P30-CA-14051)
  • National Institute of General Medical Sciences (R01GM088827)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
KRAS, NRAS, colon cancer, colonic epithelium, cell proliferation, apoptosis resistance, terminal differentiation, cancer stem cells, APC mutation, MAPK signaling, RAF inhibition, MEK, Ras effector pathways, tumor progression, genetically modified mice
MeSH terms
Animals, Cell Differentiation, Colonic Neoplasms, Epithelium, Homeostasis, Humans, Mice, Transgenic, Mutation, Genes, ras, Signal Transduction, Apoptosis, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review